# Prostate Cancer Risk Dial Citations

*This document contains the peer-reviewed studies and citations that provide the relative risk and prevalence data used to calculate the weights in the Harrison Healthcare Risk Dial for prostate cancer.*

## Table of Contents
- [5-a reductase inhibitors](#5-a-reductase-inhibitors)
- [Age](#age)
- [Ejaculation frequency](#ejaculation-frequency)
- [Family history](#family-history-14)
- [Gonorrhoea](#gonorrhoea)
- [Race](#race)
- [Sexual activity and STIs](#sexual-activity-and-stis)
- [Syphilis](#syphilis)
- [Tomato sauce](#tomato-sauce)

---
  
### 5-a reductase inhibitors
 - **Relative risk:**
   - Hu, X., Wang, Y.-H., Yang, Z.-Q., Shao, Y.-X., Yang, W.-X., & Li, X. (2020). Association of 5-alpha-reductase inhibitor and prostate cancer incidence and mortality: a meta-analysis. *Translational Andrology and Urology*, 9(6), 2519–2532. [DOI: 10.21037/tau-20-843](https://doi.org/10.21037/tau-20-843)
      - JBI Score: 100 [See report](../jbi-reports/Hu%20et%20al.%20(2020).md)

 - **Prevalence:**
   - Wallerstedt, A., Strom, P., Gronberg, H., Nordstrom, T., & Eklund, M. (2018). Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors—A Large Population-Based Prospective Study. *JNCI: Journal of the National Cancer Institute*, 110(11), 1216–1221. [DOI: 10.1093/jnci/djy036](https://doi.org/10.1093/jnci/djy036)
      - JBI Score: 95.5 [See report](../jbi-reports/Wallerstedt%20et%20al.%20(2018).md)

### Age
 - **Relative risk:**
    - Surveillance Research Program, National Cancer Institute. (2024). SEER*Explorer: An interactive website for SEER cancer statistics. Retrieved January 15, 2024, from https://seer.cancer.gov/statistics-network/explorer/. Data source: SEER Incidence Data, November 2024 Submission (1975-2022), SEER 21 registries.

 - **Prevalence:**
    - U.S. Census Bureau. (2021). Age and Sex Composition in the United States, Table 1: Population by Age and Sex 2021 [Dataset]. Retrieved from https://www.census.gov/data/tables/2021/demo/age-and-sex/2021-age-sex-composition.html


### Ejaculation frequency
 - **Relative risk and prevalence:**
   - Rider, J. R., Wilson, K. M., Sinnott, J. A., Kelly, R. S., Mucci, L. A., & Giovannucci, E. L. (2016) Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. *European Urology*, 70(6), 974-982. [DOI: 10.1016/j.eururo.2016.03.027](https://doi.org/10.1016/j.eururo.2016.03.027)
      - JBI Score: 100 [See report](../jbi-reports/Rider%20et%20al.%20(2016).md)

### Family history
 - **Relative risk:**
   - Watkins Bruner, D., Moore, D., Parlanti, A., Dorgan, J., & Engstrom, P. (2003). Relative risk of prostate cancer for men with affected relatives: Systematic review and meta‐analysis. *International Journal of Cancer*, 107(5), 797–803. [DOI: 10.1002/ijc.11466](https://doi.org/10.1002/ijc.11466)
      - JBI Score: 95.5 [See report](../jbi-reports/Bruner%20et%20al.%20(2003).md)

 - **Prevalence:**
   - Barber, L., Gerke, T., Markt, S. C., Peisch, S. F., Wilson, K. M., Ahearn, T., Giovannucci, E., Parmigiani, G., & Mucci, L. A. (2018). Family History of Breast or Prostate Cancer and Prostate Cancer Risk. *Clinical Cancer Research*, 24(23), 5910–5917. [DOI: 10.1158/1078-0432.ccr-18-0370](https://doi.org/10.1158/1078-0432.ccr-18-0370)
      - JBI Score: 90.9 [See report](../jbi-reports/Barber%20et%20al.%20(2018).md)

### Gonorrhoea
 - **Relative risk:**
   - Dennis, L. K., & Dawson, D. V. (2002). Meta-Analysis of Measures of Sexual Activity and Prostate Cancer. *Epidemiology*, 13(1), 72–79. [DOI: 10.1097/00001648-200201000-00012](https://doi.org/10.1097/00001648-200201000-00012)
      - JBI Score: 86.4 [See report](../jbi-reports/Dennis%20&%20Dawson%20(2002).md)

- **Prevalence:**
   - Public Health Agency of Canada. (2023, February 13). Chlamydia, gonorrhea and infectious syphilis in Canada: 2020 (infographic) [Infographic]. Retrieved from https://www.canada.ca/en/public-health/services/publications/diseases-conditions/chlamydia-gonorrhea-infectious-syphilis-canada-2020-infographic.html

### Race
 - **Relative risk:**
    - Surveillance Research Program, National Cancer Institute. (2024). SEER*Explorer: An interactive website for SEER cancer statistics. Retrieved January 15, 2024, from https://seer.cancer.gov/statistics-network/explorer/. Data source: SEER Incidence Data, November 2024 Submission (1975-2022), SEER 21 registries.

- **Prevalence:**
    - USAFacts. (2021). Our changing population: United States population between January 1, 2020 and January 1, 2021. Retrieved from https://usafacts.org/data/topics/people-society/population-and-demographics/our-changing-population/?endDate=2021-01-01&startDate=2020-01-01

### Syphilis
 - **Relative risk:**
   - Dennis, L. K., & Dawson, D. V. (2002). Meta-Analysis of Measures of Sexual Activity and Prostate Cancer. *Epidemiology*, 13(1), 72–79. [DOI: 10.1097/00001648-200201000-00012](https://doi.org/10.1097/00001648-200201000-00012)
      - JBI Score: 86.4 [See report](../jbi-reports/Dennis%20&%20Dawson%20(2002).md)

- **Prevalence:**
   - Public Health Agency of Canada. (2023, February 13). Chlamydia, gonorrhea and infectious syphilis in Canada: 2020 (infographic) [Infographic]. Retrieved from https://www.canada.ca/en/public-health/services/publications/diseases-conditions/chlamydia-gonorrhea-infectious-syphilis-canada-2020-infographic.html

### Tomato sauce
 - **Relative risk and prevalence:**
    - Graff, R. E., Pettersson, A., Lis, R. T., Ahearn, T. U., Markt, S. C., Wilson, K. M., ... Mucci, L. A. (2016) Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. *The American Journal of Clinical Nutrition*, 103(3), 851-860. [DOI: 10.3945/ajcn.115.118703](https://doi.org/10.3945/ajcn.115.118703)
      - JBI Score: 95.5 [See report](../jbi-reports/Graff%20et%20al.%20(2016).md)